Oral cancer and potentially malignant disorders: red flags, referral and biopsy

Clinical scope and immediate priorities

Oral squamous cell carcinoma has better outcomes when detected early, and dental professionals are well placed to recognise lesions before patients seek medical care. The key principle is persistence and clinical concern: a lesion that does not resolve as expected after removal of an obvious traumatic cause needs a defined review or referral plan rather than indefinite observation. Oral and dental presentations sit at the interface of local disease, systemic health and medication safety. Definitive dental treatment is often more important than repeated courses of symptomatic medication. Clinicians should recognise spreading infection, airway risk, cancer warning signs, bleeding risk and medication-related complications, while coordinating with medical teams when systemic disease changes procedural risk.

Recognition and differential diagnosis

Red flags include persistent ulceration, induration, unexplained red or mixed red-white patches, persistent neck mass, unexplained tooth mobility, non-healing extraction site, dysphagia, odynophagia, voice change, unilateral otalgia and altered tongue mobility or sensation. Tobacco and alcohol increase risk, but oral cancer also occurs in patients without traditional risk factors. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Perform systematic examination of lips, buccal mucosa, gingivae, tongue including lateral/ventral surfaces, floor of mouth, palate and oropharyngeal region, with neck-node assessment. Document lesion dimensions, site, surface, firmness and photographs where governance permits. Potentially malignant disorders such as leukoplakia, erythroplakia and oral lichen planus require risk-based specialist evaluation rather than diagnosis from appearance alone. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Refer urgently according to the national suspected-cancer pathway when malignancy is possible. Definitive diagnosis requires tissue biopsy interpreted with the clinical context; avoid destructive treatment of an unexplained lesion before diagnosis. Address tobacco and alcohol use and maintain nutrition and oral health during investigation. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Airway compromise, major bleeding, inability to swallow or rapidly progressive neck disease requires emergency assessment rather than routine cancer referral. Neurological symptoms or severe trismus can indicate advanced local disease and should increase urgency. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. After benign diagnosis, ensure the lesion resolves or follow the specialist surveillance plan. Patients treated for head and neck cancer need coordinated dental prevention before and after radiotherapy, including management of xerostomia, caries and osteoradionecrosis risk.

Common pitfalls and safety checks

Do not reassure solely because the patient does not smoke. Persistent oral ulceration requires a documented review or referral endpoint. Erythroplakia and mixed red-white lesions can carry substantial dysplasia risk. Avoid empiric destructive treatment before diagnosis of an unexplained persistent lesion. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Implementation requires coordination between dental and medical care when systemic disease or medicines alter procedural risk. Record the dental diagnosis, planned source control, analgesic or antimicrobial rationale and any advice obtained from the prescribing clinician. Where urgent dental access is limited, safety-net explicitly for spreading infection, airway symptoms, uncontrolled bleeding or suspected malignancy. Preventive care, fluoride exposure, periodontal maintenance and smoking cessation should be integrated into follow-up because repeated emergency treatment without prevention creates avoidable morbidity. National dental formularies and scope-of-practice rules should be followed for operational prescribing details.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.